As martinostat and imatinib co-treatment synergistically induced apoptosis in CML cells, we investigated how this combination influenced the BCR-ABL signaling pathway, a principal driver of CML pathogenesis. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.